Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Johanna OechteringKerstin SteinSabine A SchaedelinAleksandra M MaceskiAnnette OrlethStephanie MeierEline WillemseFerhan QureshiIngmar HeijnenAxel RegeniterTobias J DerfussPascal BenkertMarcus D' SouzaMarguerite LimbergBettina Fischer-BarnicolJens KuhleStefanie MuellerSalmen AnkePatrice H LaliveClaire BridelCaroline PotRenaud A Du PasquierClaudio GobbiHeinz WiendlCristina GranzieraLudwig KapposMarten TrendelenburgDavid LeppertJan D LünemannJens Kuhlenull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
CNS-compartmentalized activation of the classical and alternative pathways of complement is increased in CIS/MS and associated with the presence of an intrathecal IgM production. Increased complement activation within the CSF correlates with EDSS, future MSSS, and NfL levels, supporting the concept that complement activation contributes to MS pathology and disease progression. Complement inhibition should be explored as therapeutic target to attenuate disease severity and progression in MS.